Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
[{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Allakos"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$57.2 million","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Tiziana Life Sciences"},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Avexegen Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of IBDs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hoth Therapeutics"},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo EU","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Inks $5 M Non-dilutive Financing Involving Sale of Royalty Rights of Mytesi COVID-related Indication Revenue Stream","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Jaguar Health"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tauriga Sciences"},{"orgOrder":0,"company":"Alvogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Alvogen"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraGin\u00ae, Developed by NuLiv Science, Demonstrates Improvements in Gut Health in Human Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"NuLiv Science"},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Infinant Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinant Health Announces Submission of Orphan Drug Designation Application","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Infinant Health"}]

Find Novel Gastroenterology Drugs in Clinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications.

            Lead Product(s): Capeserod

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: First Wave BioPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 14, 2023

            Sanofi Company Banner

            WBC 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.

            Lead Product(s): INF108

            Therapeutic Area: Gastroenterology Product Name: INF108

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 02, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NuLiv Science demonstrate the potential of AstraGin® to support overall gut health and well-being, positioning it as a promising solution for individuals with UC and other gut-related challenges.

            Lead Product(s): AstraGin

            Therapeutic Area: Gastroenterology Product Name: AstraGin

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            XIFAXAN (rifaximin) is a 2 week prescription treatment that provided up to 6 months of relief from IBS-D symptoms of abdominal pain and diarrhea in a clinical trial.

            Lead Product(s): Rifaximin

            Therapeutic Area: Gastroenterology Product Name: Rifaximin-Generic

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tauriga commenced the development of a proprietary Kratom extract infused supplement chewing gum for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment).

            Lead Product(s): Kratom Extract

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.

            Lead Product(s): Crofelemer

            Therapeutic Area: Gastroenterology Product Name: Mytesi

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Napo EU

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Hoth plans to investigate the therapeutic potential of the HT-003 API using relevant ex vivo tissue models and other in vitro molecular studies.

            Lead Product(s): HT-003

            Therapeutic Area: Gastroenterology Product Name: HT-003

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Isoprene Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Avexegen will use the NIH funds to develop an orally efficacious, NRG-4-based drug product with localized action in the gut and a superior safety profile.

            Lead Product(s): Neuregulin-4-based therapy

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Funding February 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tiziana intends to use the net proceeds to advance the clinical development of Foralumab, to initiate a trial in HCC patients with Milciclib, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes

            Lead Product(s): Foralumab

            Therapeutic Area: Gastroenterology Product Name: TZLS-401

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $57.2 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AK002, an Anti-Siglec-8 antibody, depletes tissue eosinophils and improves dysphagia symptoms in patients with eosinophilic esophagitis.

            Lead Product(s): Lirentelimab

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY